Patients

[Webinar] Real evidence from real experiences: Patient Centric Evidence
Healthcare Webinar

[Webinar] Real evidence from real experiences: Patient Centric Evidence

Regulators, payers and clinicians are asking for more than traditional real world evidence (RWE). They want to understand how treatments affect people’s daily lives - not just what is written in the case report form. But how can you build patient-centric evidence that stands up to scientific, regulatory and commercial scrutiny?
A photo of a woman on a dark blue background
Healthcare Survey

Real-World Evidence

Amplifying the Patient's Voice with Real-World Evidence
Ipsos | Pov | Pharma | Healthcare
Public Health Publication

A guide to better pharma demand research

Discover the three essential steps for optimizing the quality and reliability of demand research.
Ipsos | Healthcare
Healthcare Publication

Respiratory Syncytial Virus : The race to market continues

The first wave of Ipsos’s Syndicated Global RSV study, fielded in 8 markets in Europe.
Ipsos | Research | Healthcare | respiratory syncytial virus
Healthcare Publication

RSV: On the verge of change

After decades of failed attempts, the respiratory syncytial virus (RSV) treatment and vaccine landscape is on the verge of profound change.
Ipsos | Whitepaper | Healthcare | Pharma | Segmentation
Healthcare Publication

The future of healthcare segmentations

As the healthcare sector evolves at speed, pharma needs an improved framework to guide its marketing effort and answer the eternal business questions: who to target and how.
Ipsos | healthcare | health | patients
Healthcare Publication

Oncology: the power of holistic insights

Understanding why real-world treatment in oncology can be sub-optimal – and what can be done about it.
The patient & caregiver experience of living with Alzheimer’s Disease
Healthcare Publication

The patient & caregiver experience of living with Alzheimer’s disease

The Untenable Journey
Ipsos | Multiple Sclerosis | Healthcare | White Paper
Healthcare Publication

A new era in multiple sclerosis

Momentum continues to build in the use of high-efficacy, disease modifying therapies (DMTs) as a first choice for treating multiple sclerosis. How is this being influenced by the availability of anti-CD20s, a new class of DMT? Will future new therapy classes change the paradigm even further?
Ipsos | White paper | Genetics | Healthcare
Healthcare Publication

Gene Therapies: The Moment of Truth

Are physicians and patients ready?
1 - 9 of 44 items